Skip to main content

In this blog we summarise the results of modelling for an Omicron variant outbreak of Covid-19 in NZ by the Institute of Health Metrics and Evaluation.

This work suggests that in an outbreak that begins in January, the number of cases in hospital might peak at 2,790 (95%CI: 120 to 9,070) in early March 2022. Cumulative additional deaths might be 400 by 1 May, near the end of the outbreak (peaking at 10 deaths per day [95%CI: 0 to 50]). While there are various limitations and uncertainties with all such modelling, our impression is that this work is of high quality and should be considered by NZ policy-makers. But other factors, such as the social and economic disruption from such an Omicron outbreak, should also be important considerations in guiding preparations and preventive measures.

We have previously written about the need for more preparations in Aotearoa New Zealand (NZ) concerning a future national outbreak of Omicron variant of SARS-CoV-2 (our pre-Christmas blog and a blog last week). The NZ Government is obviously taking this threat seriously with a recent suspension of future places in MIQ. However, this change will not have an impact on arriving cases until March 2022. Therefore, substantially reducing the risk now will probably require a rapid and marked reduction of incoming international flights from some countries (ie, until their outbreaks subside in coming weeks).

But what is the likely impact of an Omicron outbreak in NZ if a border failure occurs? In this blog we look at the results of modelling by the Institute of Health Metrics and Evaluation (IHME) at the University of Washington in the US. This organisation is producing Covid-19 model results for nearly all countries in the world ( They describe their model as being “a hybrid model that combines both a statistical modeling approach and a disease transmission approach, leveraging the strengths of both types of models, and scaling the results of the disease transmission model to the results of the statistical model.”

Findings of the IHME modelling for NZ

The modelling results for NZ are all shown online: and we have detailed some key parameters in the Appendix to this blog. Summarised results for the reference scenario and two additional scenarios are in Table 1 below.

These findings suggest that for an outbreak of the Omicron variant in NZ, taking off in January, the number of cases in hospital might peak at 2,790 in early March 2022 (Figure 1). But this estimate comes with high uncertainty as the 95% confidence interval (95%CI) around this 2,790 figure is large at: 120 to 9,070. Cumulative additional deaths might be 400 by 1 May, (peaking at 10 deaths per day [95%CI: 0 to 50]; Figure 2). Further deaths are considered likely to occur in subsequent weeks, although daily deaths are down to 1-2 per day in early May when the modelling run ends (Figure 2). Relative to the reference scenario, both hospitalisations and deaths are reduced in the “third dose” scenario, and even further in the “80% mask coverage” scenario (Table 1). The outbreaks had a duration of around three months.

IHME also considers the impact on the NZ hospital system (Figure 23.1 in its NZ report). This graphic shows the hospital system moving into “high stress” in February (defined as 10-19% occupancy with Covid-19 patients). It then moves to “moderate stress” (5-9% occupancy) in March and then moves to “low stress” (<5% occupancy) in April. For ICU occupancy, there is a period of “extreme stress” (≥60% occupancy) from February to April (Figure 24.1 in IHME’s NZ report). In the comparison countries in the same region, this period of “extreme stress” for ICUs is a bit shorter for Australia, presumably due to higher ICU bed capacity per capita in that country.

Table 1: Projected impact of an Omicron outbreak in NZ as modelled by IHME (modelled from 10 January and data abstracted by us to generate this table)

Notes: * The results for the “reference scenario” were the same as the “reduced vaccine hesitancy scenario” so we did not show the latter in this summary table.

** Assumes that 100% of those who have received two doses of vaccine will get a third dose at 6 months (which might be conservative given New Zealanders are encouraged to get a third dose/booster at 4 months).

Figure 1: Projected impact of an Omicron outbreak in NZ as modelled by IHME showing hospital bed and ICU bed demand for Covid-19 cases (figure re-produced by us from downloaded IHME data)

Figure 2: Projected impact of an Omicron outbreak on daily Covid-19 deaths in NZ as modelled by IHME (for the reference scenario [current projection] and two additional scenarios; figure re-produced by us from downloaded IHME data)

Comment on strengths and limitations of the IHME modelling

A strength of IHME modelling is that it comes from an organisation with a very strong track record for analysing health data (with some of the best epidemiologists, health data scientists and computer scientists in the world). This group regularly publishes their global burden of disease work in top scientific journals such as the Lancet and their key team members are involved in publications on Covid-19 modelling in top journals (eg, this study). Also a leading team member (Prof Chris Murray) has published on the performance of Covid-19 mortality modelling. Furthermore, our impression from what we understand of Omicron outbreaks in high-income countries (and what we are seeing occur in Australia at present), is that these modelling results for NZ by IHME have reasonable face validity for the point estimates of various scenarios.

Nevertheless, all such modelling has limitations and policy-makers need to consider these modelling estimates in the light of the following:

  • There is no information on differential health impacts by ethnicity or socio-economic status (yet avoiding health inequities are important considerations, especially in NZ where Covid-19 has had much worse impacts on Māori and Pasifika populations).
  • The modelling just considers the Omicron variant and yet it is possible that in coming months NZ could experience both an Omicron outbreak and a persisting Delta variant outbreak (although the latter could potentially be rapidly displaced by Omicron). Any such persisting dual variant outbreak could result in higher burdens of hospitalisations and deaths relative to the results in Table 1.
  • While the IHME modelling considers some NZ-specific control factors, this is incomplete (eg, see footnote to Table 1 concerning the timing of booster doses). Furthermore, IHME data on ICU capacity in NZ might over-estimate true capacity (given a recent report on the very constrained ICU capacity in NZ at present). In particular, more sophisticated NZ-specific modelling would consider such issues as waning immunity levels for different age/ethnicity/occupation groups based on the timing of vaccination for these different groups (albeit a very complex modelling task). New Zealanders may also take an Omicron outbreak more seriously than the populations of other countries – and hence be more vigilant than expected with mask use (including using higher quality masks, such as N95s), physical distancing and such measures as working from home.
  • Health impacts not considered in this IHME modelling include long-Covid amongst those infected and arising from delays in managing non-Covid-19 conditions (though IHME do estimate levels of “stress” on the hospital system). Of course severe Covid-19 outbreaks can also disrupt the health system at the primary care level and the running of preventive programmes (eg, routine childhood immunisation and screening programmes).

As well as considering the strengths and weaknesses of this IHME modelling, policy-makers will need to consider the potential social and economic disruption from an Omicron outbreak. This impact could be substantial given the severe strain seen on parts of Australian society at present. The model finding of periods of “high stress” on the hospital system and of “extreme stress” on ICU bed occupancy in NZ, suggests a risk of significant impacts on delivery of non-Covid-19 health care. As such there would seem to be a strong case to further delay an Omicron outbreak in NZ by reducing incoming arrivals of potentially infected travellers and reducing the burden on the MIQ system. This action will give more time for NZ to increase booster dose coverage, to vaccinate 5-11 year olds, and to learn from places like Australia about how best to protect the hospital system and critical supply lines.

Appendix – Selective notes on the IHME modelling and parameters used

This Appendix details some key aspects of IHME Covid-19 modelling (please see the specific NZ Report by IHME and this FAQ for additional details).

The model was run on 12 January, 2022, “with data through January 10, 2022”.

Reference scenario characteristics:

  • “Vaccines are distributed at the expected pace. Brand- and variant-specific vaccine efficacy is updated using the latest available information from peer-reviewed publications and other reports.
  • Future mask use is the mean of mask use over the last 7 days.
  • Mobility increases as vaccine coverage increases.” [Mobility data is measured by smartphone app use in NZ].
  • “Omicron variant spreads according to our flight and local spread model.
  • 80% of those who have had two doses of vaccine (or one dose for Johnson & Johnson) receive a third dose at 6 months after their second dose.”

Vaccination coverage data was as per 10 January 2022: “83% of people in New Zealand have received at least one vaccine dose and 78% are fully vaccinated.” (It appears that these values don’t increase into the future according to Figure 20.1 in the NZ Report).

“We have modified the model to allow the incubation time to vary by variant. For Omicron, we assume it is distributed between 1 and 4 days, skewed toward 1 day. For all other variants, we assume it is 3 to 5 days, skewed toward 3 days.”

From Figure 10.1 (in the NZ Report) the infection-fatality rate (IFR) on 10 January 2022 is <0.2% (ie, the same category as for Australia). “This is estimated as the ratio of COVID-19 deaths to estimated daily COVID-19 infections.” Of note is if the peak deaths per day is divided by the peak infections per day (reference scenario, Table 1), this gives an IFR of 10/71,370 or 0.014%.

Vaccination effectiveness against the Omicron variant of the Pfizer/BioNTech vaccine: 44% against infection and 72% against “severe disease”.

Seasonality is considered: “seasonal disease transmission patterns where COVID-19 transmission appears to increase during the fall [autumn] and winter”.

* Author details: All authors are with the Department of Public Health, University of Otago Wellington.


Public Health Expert Briefing (ISSN 2816-1203)

About the Briefing

Public health expert commentary and analysis on the challenges facing Aotearoa New Zealand and evidence-based solutions.


Briefing CTA

Public Health Expert Briefing

Get the latest insights from the public health research community delivered straight to your inbox for free. Subscribe to stay up to date with the latest research, analysis and commentary from the Public Health Expert Briefing.